Digital information and support app for people starting neoadjuvant therapy for pancreatic cancer
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
NA · Massachusetts General Hospital · NCT07047807
This pilot will test whether the PDAC-PATHWAYS app is feasible and acceptable for people starting neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT07047807 on ClinicalTrials.gov |
What this trial studies
PDAC-PATHWAYS is a digital app that provides informational and supportive-care content for patients initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma. The overall program has two parts: an open pilot to refine the app (Part 1) and a pilot randomized controlled component (Part 2) that randomizes participants to PDAC-PATHWAYS versus usual care after a baseline survey. This record describes Part 2, which will collect feasibility and acceptability outcomes to determine whether a larger randomized trial is practical. Eligible participants are adults within eight weeks of deciding to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC who can read and speak English, with exclusion for comorbid conditions that would interfere with participation.
Who should consider this trial
Good fit: Adults (≥18) with newly diagnosed, non-metastatic PDAC who are within eight weeks of deciding to start neoadjuvant therapy and who can read and speak English.
Not a fit: Patients with significant comorbid conditions that interfere with participation, non-English speakers, or those already receiving similar digital support may not receive benefit from this specific intervention.
Why it matters
Potential benefit: If successful, the app could improve patient education, symptom management, and emotional support during neoadjuvant therapy.
How similar studies have performed: Digital supportive-care apps have shown promise in other cancer populations for improving symptom management and patient experience, but PDAC-specific randomized data are limited, so this application is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥18 years * Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC * Able to comprehend and speak English Exclusion Criteria: * Comorbid health condition that would interfere with study participation, as identified by the cancer care team
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Study coordinator: Kelsey Lau-Min, MD, MSCE
- Email: klau-min@mgh.harvard.edu
- Phone: 617-724-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: PDAC - Pancreatic Ductal Adenocarcinoma